These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 27203677)

  • 1. Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma.
    Deng YR; Liu WB; Lian ZX; Li X; Hou X
    Oncotarget; 2016 Jun; 7(25):38292-38305. PubMed ID: 27203677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma.
    Chen J; Jin R; Zhao J; Liu J; Ying H; Yan H; Zhou S; Liang Y; Huang D; Liang X; Yu H; Lin H; Cai X
    Cancer Lett; 2015 Oct; 367(1):1-11. PubMed ID: 26170167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma.
    Nagai T; Arao T; Furuta K; Sakai K; Kudo K; Kaneda H; Tamura D; Aomatsu K; Kimura H; Fujita Y; Matsumoto K; Saijo N; Kudo M; Nishio K
    Mol Cancer Ther; 2011 Jan; 10(1):169-77. PubMed ID: 21220499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression.
    Ha TY; Hwang S; Moon KM; Won YJ; Song GW; Kim N; Tak E; Ryoo BY; Hong HN
    Anticancer Res; 2015 Apr; 35(4):1967-76. PubMed ID: 25862849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma.
    Mir N; Jayachandran A; Dhungel B; Shrestha R; Steel JC
    Curr Cancer Drug Targets; 2017; 17(8):698-706. PubMed ID: 28460616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
    PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells.
    Liu J; Liu Y; Meng L; Ji B; Yang D
    Int J Med Sci; 2017; 14(6):523-529. PubMed ID: 28638267
    [No Abstract]   [Full Text] [Related]  

  • 8. Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling.
    Zhang PF; Li KS; Shen YH; Gao PT; Dong ZR; Cai JB; Zhang C; Huang XY; Tian MX; Hu ZQ; Gao DM; Fan J; Ke AW; Shi GM
    Cell Death Dis; 2016 Apr; 7(4):e2201. PubMed ID: 27100895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum response factor induces epithelial to mesenchymal transition with resistance to sorafenib in hepatocellular carcinoma.
    Bae JS; Noh SJ; Kim KM; Jang KY; Chung MJ; Kim DG; Moon WS
    Int J Oncol; 2014 Jan; 44(1):129-36. PubMed ID: 24173109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regorafenib reverses HGF-induced sorafenib resistance by inhibiting epithelial-mesenchymal transition in hepatocellular carcinoma.
    Chen W; Yang J; Zhang Y; Cai H; Chen X; Sun D
    FEBS Open Bio; 2019 Feb; 9(2):335-347. PubMed ID: 30761258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic effect of sorafenib and vitamin K on suppression of hepatocellular carcinoma cell migration and metastasis.
    Ha TY; Hwang S; Hong HN; Choi YI; Yoon SY; Won YJ; Song GW; Kim N; Tak E; Ryoo BY
    Anticancer Res; 2015 Apr; 35(4):1985-95. PubMed ID: 25862851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.
    Sprinzl MF; Reisinger F; Puschnik A; Ringelhan M; Ackermann K; Hartmann D; Schiemann M; Weinmann A; Galle PR; Schuchmann M; Friess H; Otto G; Heikenwalder M; Protzer U
    Hepatology; 2013 Jun; 57(6):2358-68. PubMed ID: 23424039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
    Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W
    BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-101 targets DUSP1 to regulate the TGF-β secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinoma.
    Wei X; Tang C; Lu X; Liu R; Zhou M; He D; Zheng D; Sun C; Wu Z
    Oncotarget; 2015 Jul; 6(21):18389-405. PubMed ID: 26158762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion.
    Sprinzl MF; Puschnik A; Schlitter AM; Schad A; Ackermann K; Esposito I; Lang H; Galle PR; Weinmann A; Heikenwälder M; Protzer U
    J Hepatol; 2015 Apr; 62(4):863-70. PubMed ID: 25463538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
    You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
    J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.
    Horwitz E; Stein I; Andreozzi M; Nemeth J; Shoham A; Pappo O; Schweitzer N; Tornillo L; Kanarek N; Quagliata L; Zreik F; Porat RM; Finkelstein R; Reuter H; Koschny R; Ganten T; Mogler C; Shibolet O; Hess J; Breuhahn K; Grunewald M; Schirmacher P; Vogel A; Terracciano L; Angel P; Ben-Neriah Y; Pikarsky E
    Cancer Discov; 2014 Jun; 4(6):730-43. PubMed ID: 24687604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma.
    Erös de Bethlenfalva-Hora C; Mertens JC; Piguet AC; Kettenbach J; Schmitt J; Terracciano L; Weimann R; Dufour JF; Geier A
    Clin Sci (Lond); 2014 Feb; 126(3):243-52. PubMed ID: 23822114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive role of the neutrophil-to-lymphocyte ratio in patients with advanced hepatocellular carcinoma receiving sorafenib.
    Tanoglu A; Karagoz E
    Asian Pac J Cancer Prev; 2014; 15(2):1063. PubMed ID: 24568452
    [No Abstract]   [Full Text] [Related]  

  • 20. New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies.
    Niu L; Liu L; Yang S; Ren J; Lai PBS; Chen GG
    Biochim Biophys Acta Rev Cancer; 2017 Dec; 1868(2):564-570. PubMed ID: 29054475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.